All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): STC-15
Therapeutic Area: Oncology Product Name: STC-15
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
STC-15 is an orally bioavailable, small molecule METTL3 inhibitor targeting an entirely new mechanism of action (modulation of RNA epigenetics) to treat acute myeloid leukaemia (AML) and other solid and haematological cancers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EPS 201
Therapeutic Area: Oncology Product Name: EPS 201
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $1.3 million Upfront Cash: Undisclosed
Deal Type: Funding October 21, 2020
Details:
Epsilogen will collaborate with King’s College London (KCL) and use the funding from the grant to further develop the company’s novel cancer immunotherapeutic EPS 201.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BT7480
Therapeutic Area: Oncology Product Name: BT7480
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
BT7480 is a novel, fully synthetic TICA targeting Nectin-4, agonizing CD137. EphA2/CD137 TICAs are comprised of Bicycles that target the tumor antigen EphA2, which is overexpressed in a range of solid tumor types and associated with poor outcomes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SDC-1802
Therapeutic Area: Oncology Product Name: SDC-1802
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The patent will protect the SDC-1802 molecule and pharmaceutical preparations thereof. Subject to certain formalities being completed, the Company expects that the patent will be granted within three months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): siRNA
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 23, 2020
Details:
Programmable Oligonucleotide Delivery System (PODS), developed by Sixfold Bioscience, is a versatile system which delivers short interfering RNA (siRNA) gene silencing cargo to specific cancer cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PYTX-002
Therapeutic Area: Oncology Product Name: PYTX-002
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Papyrus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 17, 2020
Details:
The collaboration includes the assessment of the therapeutic benefit of Papyrus’ PYTX-002, a gene replacement therapy that will confer ‘cellular pharmacy’ properties on a CAR-T cell therapy developed by Oxford Biomedica, initially in preclinical in vivo models of solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AVA6000
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: LG Chem
Deal Size: $453.5 million Upfront Cash: Undisclosed
Deal Type: Expanded Partnership August 18, 2020
Details:
Under the terms of the extended agreement, LG Chem has the exclusive rights to develop and commercialise, on a world-wide basis, Avacta’s Affimer PD-L1 inhibitor with Affimer XT serum half-life extension.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lentiviral vector
Therapeutic Area: Oncology Product Name: LentiVector
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Beam Therapeutics Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 03, 2020
Details:
The DMLA grants Beam a non-exclusive license to Oxford Biomedica’s LentiVector® platform for its application in next generation CAR-T programmes in oncology and puts in place a three year Clinical Supply Agreement.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TGL-100
Therapeutic Area: Oncology Product Name: TGL-100
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: University of Southampton
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 29, 2020
Details:
The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tetravalent bispecific antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Merck Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 16, 2020
Details:
This is the second license option exercised by Merck KGaA, Darmstadt, Germany who, in May 2019, brought the first program from the collaboration into its pipeline.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
